Supplemental Financial Information - Cash Flows (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities
Net income	$ 1,284.7	$ 3,045.2	$ 382.8
Adjustments to reconcile net income to net cash flows from operating activities:
Depreciation and amortization	147.4	52.0	52.1
Equity-based compensation	154.0	163.1	105.0
Right-of-use asset impairment, net of broker fees	0.0	24.8	0.0
Non-cash performance allocations and incentive fees, net	393.6	(1,670.7)	(631.8)
Non-cash principal investment (income) loss	(553.4)	(618.5)	534.4
Other non-cash amounts	(10.3)	29.1	(2.9)
Purchases of investments	(629.9)	(276.7)	(271.3)
Proceeds from the sale of investments	474.9	668.4	307.5
Payments of contingent consideration	(5.7)	(48.0)	0.0
Changes in deferred taxes, net	(73.2)	508.4	134.5
Change in due from affiliates and other receivables	(82.5)	(25.7)	1.9
Change in deposits and other	(11.8)	(12.5)	(2.0)
Change in accounts payable, accrued expenses and other liabilities	(14.3)	105.7	(4.0)
Change in accrued compensation and benefits	(135.4)	239.0	210.1
Change in due to affiliates	1.7	0.2	(29.2)
Change in lease right-of-use assets and lease liabilities	(8.8)	4.5	(9.8)
Change in deferred revenue	4.5	35.1	16.2
Net cash (used in) provided by operating activities	(379.3)	1,791.0	(169.2)
Cash flows from investing activities
Purchases of corporate treasury investments	(69.6)	0.0	0.0
Proceeds from corporate treasury investments	50.0	0.0	0.0
Purchases of fixed assets, net	(40.6)	(41.4)	(61.2)
Purchase of Abingworth, net of cash acquired	(150.2)	0.0	0.0
Purchase of CBAM intangibles and investments	(618.4)	0.0	0.0
Net cash used in investing activities	(828.8)	(32.2)	(61.2)
Cash flows from financing activities
Borrowings under credit facilities	0.0	70.0	294.1
Repayments under credit facilities	0.0	(70.0)	(329.9)
Issuance of 4.625% subordinated notes due 2061, net of financing costs	0.0	484.1	0.0
Repurchase of 3.875% senior notes due 2023	0.0	(259.9)	0.0
Proceeds from CLO borrowings, net of financing costs	73.2	111.7	20.5
Payments on CLO borrowings	(16.7)	(232.5)	(3.8)
Payments of contingent consideration	0.0	(0.1)	(0.3)
Dividends to common stockholders	(443.6)	(355.8)	(351.3)
Payment of deferred consideration for Carlyle Holdings units	(68.8)	(68.8)	(68.8)
Contributions from non-controlling interest holders	391.2	216.2	210.0
Distributions to non-controlling interest holders	(216.8)	(94.6)	(77.8)
Common shares issued for performance allocations	38.9	4.8	0.0
Common shares repurchased	(185.6)	(161.8)	(26.4)
Change in due to/from affiliates financing activities	(81.2)	(68.7)	0.7
Net cash provided by (used in) financing activities	114.8	(242.5)	370.3
Effect of foreign exchange rate changes	(20.3)	(30.8)	21.7
(Decrease) increase in cash, cash equivalents and restricted cash	(1,113.6)	1,485.5	161.6
Cash, cash equivalents and restricted cash, beginning of period	2,475.1	989.6	828.0
Cash, cash equivalents and restricted cash, end of period	1,361.5	2,475.1	989.6
Reconciliation of cash, cash equivalents and restricted cash, end of period:
Cash and cash equivalents	1,360.7	2,469.5	987.6
Restricted cash	0.8	5.6	2.0
Total cash, cash equivalents and restricted cash, end of period	1,361.5	2,475.1	989.6
MRE
Cash flows from investing activities
Proceeds from sale, net of cash sold	0.0	5.9	0.0
Brazil management entity
Cash flows from investing activities
Proceeds from sale, net of cash sold	$ 0.0	3.3	0.0
Subordinated Notes Due 2061
Reconciliation of cash, cash equivalents and restricted cash, end of period:
Interest rate (percent)	4.625%
Subordinated Notes Due 2023
Reconciliation of cash, cash equivalents and restricted cash, end of period:
Interest rate (percent)	3.875%
Consolidated Operating Entities
Cash flows from operating activities
Net income	$ 1,248.6	3,042.5	374.7
Adjustments to reconcile net income to net cash flows from operating activities:
Depreciation and amortization	147.4	52.0	52.1
Equity-based compensation	154.0	163.1	105.0
Right-of-use asset impairment, net of broker fees	0.0	24.8	0.0
Non-cash performance allocations and incentive fees, net	387.5	(1,670.7)	(631.8)
Non-cash principal investment (income) loss	(501.5)	(628.9)	568.0
Other non-cash amounts	(10.3)	29.1	(2.9)
Purchases of investments	(737.7)	(384.5)	(397.4)
Proceeds from the sale of investments	498.0	708.3	332.1
Payments of contingent consideration	(5.7)	(48.0)	0.0
Changes in deferred taxes, net	(73.2)	508.4	134.5
Change in due from affiliates and other receivables	(82.3)	(25.1)	1.2
Change in deposits and other	(11.8)	(12.5)	(2.0)
Change in accounts payable, accrued expenses and other liabilities	(14.3)	105.7	(4.0)
Change in accrued compensation and benefits	(135.4)	239.0	210.1
Change in due to affiliates	1.7	0.2	(29.2)
Change in lease right-of-use assets and lease liabilities	(8.8)	4.5	(9.8)
Change in deferred revenue	4.5	35.1	16.2
Net cash (used in) provided by operating activities	860.7	2,143.0	716.8
Cash flows from investing activities
Purchases of corporate treasury investments	(69.6)	0.0	0.0
Proceeds from corporate treasury investments	50.0	0.0	0.0
Purchases of fixed assets, net	(40.6)	(41.4)	(61.2)
Purchase of Abingworth, net of cash acquired	(150.2)	0.0	0.0
Purchase of CBAM intangibles and investments	(618.4)	0.0	0.0
Net cash used in investing activities	(828.8)	(32.2)	(61.2)
Cash flows from financing activities
Borrowings under credit facilities	0.0	70.0	294.1
Repayments under credit facilities	0.0	(70.0)	(329.9)
Issuance of 4.625% subordinated notes due 2061, net of financing costs	0.0	484.1	0.0
Repurchase of 3.875% senior notes due 2023	0.0	(259.9)	0.0
Proceeds from CLO borrowings, net of financing costs	73.2	111.7	20.5
Payments on CLO borrowings	(16.7)	(232.5)	(3.8)
Payments of contingent consideration	0.0	(0.1)	(0.3)
Dividends to common stockholders	(443.6)	(355.8)	(351.3)
Payment of deferred consideration for Carlyle Holdings units	(68.8)	(68.8)	(68.8)
Contributions from non-controlling interest holders	9.2	19.4	31.0
Distributions to non-controlling interest holders	(78.7)	(74.5)	(76.8)
Common shares issued for performance allocations	38.9	4.8	0.0
Common shares repurchased	(185.6)	(161.8)	(26.4)
Change in due to/from affiliates financing activities	(456.2)	(68.7)	0.7
Net cash provided by (used in) financing activities	(1,128.3)	(602.1)	(511.0)
Effect of foreign exchange rate changes	(17.2)	(23.2)	17.0
(Decrease) increase in cash, cash equivalents and restricted cash	(1,113.6)	1,485.5	161.6
Cash, cash equivalents and restricted cash, beginning of period	2,475.1	989.6	828.0
Cash, cash equivalents and restricted cash, end of period	1,361.5	2,475.1	989.6
Supplemental cash disclosures
Issuance of common shares related to the acquisition of CBAM and Abingworth	219.5	0.0	0.0
Reconciliation of cash, cash equivalents and restricted cash, end of period:
Cash and cash equivalents	1,360.7	2,469.5	987.6
Restricted cash	0.8	5.6	2.0
Total cash, cash equivalents and restricted cash, end of period	1,361.5	2,475.1	989.6
Consolidated Operating Entities | MRE
Cash flows from investing activities
Proceeds from sale, net of cash sold	0.0	5.9	0.0
Consolidated Operating Entities | Brazil management entity
Cash flows from investing activities
Proceeds from sale, net of cash sold	$ 0.0	$ 3.3	$ 0.0
Consolidated Operating Entities | Subordinated Notes Due 2061
Reconciliation of cash, cash equivalents and restricted cash, end of period:
Interest rate (percent)	4.625%
Consolidated Operating Entities | Subordinated Notes Due 2023
Reconciliation of cash, cash equivalents and restricted cash, end of period:
Interest rate (percent)	3.875%